Outcome by lymphoma subtype. Progression-free survival (top) and OS (bottom) from the day of iPET for patients with various types of B-cell non-Hodgkin lymphoma (DLBCL, primary mediastinal B-cell lymphoma [PMBCL], follicular lymphoma [FL] grade 3; left) or T-cell non-Hodgkin lymphoma (ALK⁺ ALCL, ALK⁻ peripheral T-cell lymphoma [PTCL]; right). Of 623 patients with DLBCL, 574 had DLBCL alone, and 49 had DLBCL combined with an indolent lymphoma. Of 54 patients with FL grade 3, 25 had FL grade 3a, 17 had FL grade 3b, and 12 had FL grade 3 combined with FL grade 1 or 2. Of 55 patients with ALK⁻ PTCL, 13 had ALK⁻ ALCL, 18 had angioimmunoblastic T-cell lymphoma, 20 had PTCL not otherwise specified, and 4 had unclassified T-cell lymphoma. Because the subgroups within the DLBCL, FL grade 3, and ALK⁻ PTCL cohorts had similar outcomes (supplemental Figure 1), they were combined in this analysis. No., number; p, log-rank test.